The USFDA has approved sacituzumab govitecan-hziy for the treatment of patients with refractory metastatic triple-negative breast cancer (TNBC). The therapy is targeted for patients with aggressive malignancy and for those who have already received at least two prior therapies. This drug has been granted ‘Breakthrough Therapy’ and ‘Fast Track’ designations signifying that the drug is intended for use in serious conditions. Sacituzumab govitecan-hziy is an antibody-drug conjugate that is based on the combination of a humanized monoclonal antibody directed against human trophoblast cell-surface antigen 2 (Trop-2)- and a topoisomerase I inhibitor (SN-38).
The drug enables the delivery of a high concentration of SN-38 to the tumors. Triple-negative breast cancer (TNBC) is a cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 proteins. Such type of…
